Department of Microecology, College of Basic Medical Science, Dalian Medical University, Dalian, China.
Department of Clinical Laboratory, Central Hospital of Dalian University of Technology, Dalian, China.
Gut Microbes. 2024 Jan-Dec;16(1):2334967. doi: 10.1080/19490976.2024.2334967. Epub 2024 Apr 17.
Human milk oligosaccharides (HMOs) are vital milk carbohydrates that help promote the microbiota-dependent growth and immunity of infants. Sialic acid (SA) is a crucial component of sialylated milk oligosaccharides (S-MOs); however, the effects of SA supplementation in lactating mothers on S-MO biosynthesis and their breastfed infants are unknown. Probiotic intervention during pregnancy or lactation demonstrates promise for modulating the milk glycobiome. Here, we evaluated whether SA and a probiotic (Pro) mixture could increase S-MO synthesis in lactating mothers and promote the microbiota development of their breastfed neonates. The results showed that SA+Pro intervention modulated the gut microbiota and 6'-SL contents in milk of maternal rats more than the SA intervention, which promoted colonization in neonates and immune development. Deficient 6'-SL in the maternal rat milk of knockouts (St6gal1) disturbed intestinal microbial structures in their offspring, thereby impeding immune tolerance development. SA+Pro intervention in lactating St6gal1 rats compromised the allergic responses of neonates by promoting 6'-SL synthesis and the neonatal gut microbiota. Our findings from human mammary epithelial cells (MCF-10A) indicated that the GPR41-PI3K-Akt-PPAR pathway helped regulate 6'-SL synthesis in mammary glands after SA+Pro intervention through the gut - breast axis. We further validated our findings using a human-cohort study, confirming that providing SA+Pro to lactating Chinese mothers increased S-MO contents in their breast milk and promoted gut spp. and spp. colonization in infants, which may help enhance immune responses. Collectively, our findings may help alter the routine supplementation practices of lactating mothers to modulate milk HMOs and promote the development of early-life gut microbiota and immunity.
人乳寡糖 (HMOs) 是重要的乳类碳水化合物,有助于促进婴儿依赖微生物群的生长和免疫。唾液酸 (SA) 是唾液酸化乳寡糖 (S-MO) 的重要组成部分;然而,哺乳期母亲补充 SA 对 S-MO 生物合成及其母乳喂养婴儿的影响尚不清楚。在妊娠或哺乳期进行益生菌干预已被证明可以调节乳类糖组。在这里,我们评估了 SA 和益生菌 (Pro) 混合物是否可以增加哺乳期母亲的 S-MO 合成并促进其母乳喂养新生儿的微生物群发育。结果表明,SA+Pro 干预比 SA 干预更能调节母鼠的肠道微生物群和乳中 6'-SL 含量,从而促进新生儿的定植和免疫发育。母鼠乳中 6'-SL 缺乏 (St6gal1 敲除) 会扰乱其后代肠道微生物结构,从而阻碍免疫耐受的发展。SA+Pro 干预哺乳期 St6gal1 大鼠会通过促进 6'-SL 合成和新生儿肠道微生物群来损害新生儿的过敏反应。我们从人乳腺上皮细胞 (MCF-10A) 获得的研究结果表明,GPR41-PI3K-Akt-PPAR 通路通过肠道-乳腺轴帮助调节 SA+Pro 干预后乳腺中 6'-SL 的合成。我们使用人类队列研究进一步验证了我们的发现,证实向哺乳期中国母亲提供 SA+Pro 可增加其母乳中 S-MO 的含量,并促进婴儿肠道 spp. 和 spp. 的定植,从而有助于增强免疫反应。总的来说,我们的研究结果可能有助于改变哺乳期母亲的常规补充实践,以调节乳类 HMOs 并促进早期生命肠道微生物群和免疫的发育。